Atyr Pharma Files 8-K/A Amendment
Ticker: ATYR · Form: 8-K/A · Filed: Aug 8, 2025 · CIK: 1339970
| Field | Detail |
|---|---|
| Company | Atyr Pharma Inc (ATYR) |
| Form Type | 8-K/A |
| Filed Date | Aug 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-reporting
TL;DR
Atyr Pharma filed an amendment to its 8-K, correcting/adding financial info.
AI Summary
Atyr Pharma, Inc. filed an amendment (8-K/A) on August 8, 2025, to its current report originally filed on August 7, 2025. This amendment pertains to the "Results of Operations and Financial Condition" and "Financial Statements and Exhibits" sections. The filing date as of the change is August 7, 2025.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information regarding Atyr Pharma's financial condition and operations.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.
Key Players & Entities
- Atyr Pharma, Inc. (company) — Registrant
- August 7, 2025 (date) — Date of earliest event reported
- August 8, 2025 (date) — Filing date
- 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed Form 8-K, specifically addressing the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' sections.
What is the exact date of the earliest event reported in this amendment?
The date of the earliest event reported is August 7, 2025.
When was this amendment filed with the SEC?
This amendment was filed as of August 8, 2025.
What is the principal business address of Atyr Pharma, Inc.?
The principal executive offices are located at 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121.
What is the SIC code for Atyr Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Atyr Pharma, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 685 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-07 21:33:53
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M
Filing Documents
- atyr-20250807.htm (8-K/A) — 61KB
- atyr-ex99_1.htm (EX-99.1) — 198KB
- img137952089_0.jpg (GRAPHIC) — 44KB
- 0001339970-25-000016.txt ( ) — 438KB
- atyr-20250807.xsd (EX-101.SCH) — 25KB
- atyr-20250807_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information under this Item 2.02, including Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATYR PHARMA, INC. By: /s/ Jill M. Broadfoot Jill M. Broadfoot Chief Financial Officer Date: August 7, 2025 4